Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines.

In conclusion, a combination of docetaxel with inhibitors of HER family members, such as cetuximab plus pertuzumab, may be considered for a clinical trial in ovarian carcinomas with functional receptors.